Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
出版年份 2021 全文链接
标题
Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-11-01
DOI
10.3389/fphar.2021.741451
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function
- (2021) Katia Khoury et al. BREAST CANCER RESEARCH AND TREATMENT
- Antibodies to watch in 2021
- (2021) Hélène Kaplon et al. mAbs
- Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study
- (2021) Husam Abdel‐Qadir et al. Journal of the American Heart Association
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
- (2021) Larissa A. Korde et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
- (2021) Martin Nicol et al. ESC Heart Failure
- FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer
- (2021) Preeti Narayan et al. CLINICAL CANCER RESEARCH
- Margetuximab: First Approval
- (2021) Anthony Markham DRUGS
- Return-to-work, disabilities and occupational health in the age of COVID-19
- (2021) Diane Godeau et al. SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH
- Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
- (2021) C. Corti et al. ESMO Open
- Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab
- (2021) Rita De Sanctis et al. BREAST
- Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
- (2020) Noam Pondé et al. EUROPEAN JOURNAL OF CANCER
- Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity
- (2020) James Lambert et al. HEART
- A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer
- (2020) Wala Ben Kridis et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
- (2020) Daniel Eiger et al. BRITISH JOURNAL OF CANCER
- The role of cardio-protective agents for cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies
- (2020) Hagar Elghazawy et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
- (2020) Joerg Herrmann Nature Reviews Cardiology
- Recent advances of antibody drug conjugates for clinical applications
- (2020) Pengxuan Zhao et al. Acta Pharmaceutica Sinica B
- The Preventive Role of Regular Physical Training in Ventricular Remodeling, Serum Cardiac Markers, and Exercise Performance Changes in Breast Cancer in Women Undergoing Trastuzumab Therapy—An REH-HER Study
- (2020) Katarzyna Hojan et al. Journal of Clinical Medicine
- Tucatinib: First Approval
- (2020) Arnold Lee DRUGS
- Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab
- (2020) Vincenzo Quagliariello et al. International Journal of Nanomedicine
- The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice
- (2020) Chantal Y Asselin et al. JOURNAL OF NUTRITION
- Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review
- (2020) Jenica N. Upshaw Current Oncology Reports
- Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer
- (2020) Angeliki Andrikopoulou et al. Clinical Breast Cancer
- FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer
- (2020) Mirat Shah et al. CLINICAL CANCER RESEARCH
- Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology
- (2020) Radek Pudil et al. EUROPEAN JOURNAL OF HEART FAILURE
- Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab
- (2020) Anton E. Andersson et al. ACTA ONCOLOGICA
- Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
- (2020) Antoinette R Tan et al. LANCET ONCOLOGY
- Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
- (2020) Alexandra Maria Rüger et al. Journal of the American Heart Association
- Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer
- (2020) Christian P. Houbois et al. JACC-Cardiovascular Imaging
- Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients
- (2019) Kalliopi Keramida et al. EUROPEAN JOURNAL OF HEART FAILURE
- Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer
- (2019) Hyun Ju Yoon et al. Clinical Research in Cardiology
- Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
- (2019) F. Lynce et al. BREAST CANCER RESEARCH AND TREATMENT
- Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction
- (2019) Yasin Hussain et al. BREAST CANCER RESEARCH AND TREATMENT
- SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
- (2019) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
- (2019) Guy Jerusalem et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer
- (2019) Maya Guglin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy
- (2019) Jenica N. Upshaw et al. JACC-Cardiovascular Imaging
- Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity
- (2019) Evangelos K. Oikonomou et al. JAMA Cardiology
- A pooled analysis of the cardiac events in the trastuzumab adjuvant trials
- (2019) Evandro de Azambuja et al. BREAST CANCER RESEARCH AND TREATMENT
- Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis
- (2019) Lars Michel et al. EUROPEAN JOURNAL OF HEART FAILURE
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
- (2019) Elisé G. Kaboré et al. PLOS MEDICINE
- Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab
- (2018) Quentin Jacquinot et al. BREAST
- Single Versus Standard Multiview Assessment of Global Longitudinal Strain for the Diagnosis of Cardiotoxicity During Cancer Therapy
- (2018) Paaladinesh Thavendiranathan et al. JACC-Cardiovascular Imaging
- Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
- (2018) Claudia De Lorenzo et al. OncoTargets and Therapy
- The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
- (2018) Wan-Tseng Hsu et al. Theranostics
- Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
- (2018) Gennaro Riccio et al. Frontiers in Physiology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients
- (2018) Mariana L. Henry et al. JACC-Cardiovascular Imaging
- Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities
- (2018) Maher Chaar et al. OncoTargets and Therapy
- Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
- (2018) Somaira Nowsheen et al. Journal of the American Heart Association
- Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer
- (2018) Maria C. Arciniegas Calle et al. BMC CANCER
- Cardio-protective effect of statins in patients with HER2 positive breast cancer receiving trastuzumab therapy
- (2018) Oscar Calvillo-Argüelles et al. CANADIAN JOURNAL OF CARDIOLOGY
- Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study
- (2018) Milvia Zambetti et al. EUROPEAN JOURNAL OF CANCER
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequency of Transition From Stage A to Stage B Heart Failure After Initiating Potentially Cardiotoxic Chemotherapy
- (2018) Deanna N. Jones et al. JACC-Heart Failure
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
- (2017) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study
- (2016) Mette S. van Ramshorst et al. BREAST
- Human epidermal growth factor antagonists and cardiotoxicity—A short review of the problem and preventative measures
- (2016) A. Dias et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
- (2016) Geeta Gulati et al. EUROPEAN HEART JOURNAL
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
- (2016) Ahmad Awada et al. JAMA Oncology
- Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice
- (2015) Annemiek Visser et al. ACTA ONCOLOGICA
- Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab
- (2015) M. Putt et al. CLINICAL CHEMISTRY
- Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality
- (2015) Noemi Pavo et al. HEART
- Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab
- (2015) L. Cao et al. ONCOLOGIST
- Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors
- (2015) J. M. Serrano et al. ONCOLOGIST
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
- (2014) Evandro de Azambuja et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth
- (2013) Mercedes Tkach et al. ENDOCRINE-RELATED CANCER
- Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
- (2013) Bonnie Ky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- Mechanisms of cardiotoxicity associated with ErbB2 inhibitors
- (2012) Carmine Fedele et al. BREAST CANCER RESEARCH AND TREATMENT
- High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study
- (2012) Adedayo A. Onitilo et al. BREAST CANCER RESEARCH AND TREATMENT
- Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2012) Edward H. Romond et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy
- (2012) Sinziana Seicean et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Administration of Angiotensin-Converting Enzyme Inhibitors and -Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?
- (2012) S. Oliva et al. ONCOLOGIST
- Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
- (2011) Carmine Fedele et al. BREAST CANCER RESEARCH AND TREATMENT
- Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer
- (2011) Alexandre Cochet et al. BREAST CANCER RESEARCH AND TREATMENT
- The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy
- (2011) Nazanin Fallah-Rad et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Cardioprotective Role of Probucol Against Anthracycline and Trastuzumab-Mediated Cardiotoxicity
- (2011) Jonathan R. Walker et al. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
- The Vulnerability of the Heart As a Pluricellular Paracrine Organ
- (2010) Gilles W. De Keulenaer et al. CIRCULATION RESEARCH
- Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
- (2009) M. Martin et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started